Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results Twenty-eight ...
Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results